Using individual patient data (IPD) and meta-regression methodology, researchers sought to indirectly compare the effectiveness of once-weekly (OW) semaglutide 1 mg vs once-daily (OD) empagliflozin 25 mg in patients with type 2 diabetes (T2D) inadequately controlled on metformin monotherapy. IPD for patients with T2D receiving metformin monotherapy and randomized to OW semaglutide 1 mg (SUSTAIN 2, 3, 8 trials), or to OD empagliflozin 25 mg (PIONEER 2 trial) have been involved. Findings revealed that baseline features were comparable between OW semaglutide (n = 995) and empagliflozin (n = 410). According to this indirect comparison, OW semaglutide 1 mg gives superior declines in HbA1c and body weight vs OD empagliflozin 25 mg in patients with T2D when added to metformin monotherapy.
This indirect comparison suggests that OW semaglutide 1 mg provides superior reductions in HbA1c and body weight vs OD empagliflozin 25 mg in patients with T2D when added to metformin monotherapy.